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Abstract
This issue’s recently published papers commentary takes a long
hard look at the surprisingly topically issue of oxygen. To give a
balanced perspective, topical ventilatory studies are also discussed.
Confused by oxygen?
Several recently published papers have demonstrated both
the pros and cons of oxygen therapy. They also serve to
illustrate that extrapolating from studies with experimental
animal models to the clinical arena requires great caution.
In a rat model of haemorrhagic shock, Brod and colleagues
investigated the effects of combined resuscitation with
hypertonic saline and oxygen [1]. The authors designed a
complex protocol with sequential single interventions and
compared 5 ml/kg fluid resuscitation using 0.9% and 7.5%
saline and a fraction of inspired oxygen (FiO2) of 0.21 and
1.0. They measured regional perfusion in several vascular
beds together with plasma lactate as a measure of the
adequacy of resuscitation. Their results showed that 7.5%
saline and 100% oxygen was the superior strategy. Of
particular note were the marked haemodynamic effects of
increasing the FiO2 to 1.0. The accompanying editorial [2]
considers these results in a wider clinical context. It rightly
concludes that the effects of 100% oxygen on regional blood
flow, and hence its role in resuscitation, have for too long
been neglected and warrant further investigation.
Multiple organ failure syndrome (MOFS) is the final common
pathway of critical illness. Imperatore and colleagues have
previously demonstrated that intermittent hyperbaric oxygen
(HBO) therapy is effective in attenuating this process in a
zymosan-induced MOFS model in rats. They have now
published a further study concentrating on the effects of
HBO on the coagulation cascade [3]. The zymosan insult
produced a marked coagulopathy, MOFS and a 50%
mortality at 72 hours in the control group. The intervention
group, which was subjected to two 60-minute periods of
hyperbaric (2 atmospheres absolute (ATA) oxygen (FiO2 1.0)
at 4 and 11 hours after MOFS initiation, demonstrated a
markedly attenuated coagulopathy with less severe MOFS
and a 100% survival at 72 hours.
In a related study, Buras and colleagues investigated the
efficacy of four oxygen regimens in a caecal ligation-and-
puncture model of MOFS in mice [4]. In addition to survival,
they measured bacterial load and performed experiments on
macrophage function, specifically investigating whether IL-10
has a key role in the protective effect of HBO therapy. In
comparison with the control group, which received an FiO2 of
0.21, normobaric FiO2 of 1.0 for 90 minutes at 12-hourly
intervals and HBO at 2.5 ATA for 90 minutes at 24-hourly
intervals had no effect on survival at 100 hours (mortality 80%).
HBO at 2.5 ATA for 90 minutes at 12-hourly intervals improved
survival from 20% to 70%. HBO at 3 ATA for 90 minutes at
12-hourly intervals proved be 100% lethal after approximately
30 hours. The successful strategy did not reduce the bacterial
load in the peritoneum but did reduce the load disseminated to
the spleen, suggesting that the beneficial effects were not
mediated by microbial killing. The macrophage and IL-10 data
are complex but, importantly, no benefit of HBO was
demonstrated when the experiment was repeated in IL-10-
deficient mice, suggesting that it is an essential component of
the protective effect of HBO. The enhanced lethality of the
3 ATA regime was unexpected but reinforces the serious
potential of HBO for harm as well as benefit.
By coincidence, a state-of-the-art review of the multiple
oxygen-sensitive intracellular signalling pathways, mediated
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by a series of hypoxia-inducible transcription factors, has just
been published [5]. This concise and well referenced over-
view, in particular, considers the prospect that these
pathways offer attractive therapeutic targets. Oxygen is
evidently a major regulatory factor in a wide variety of cellular
and tissue processes. The signal transduction pathways for
hypoxia are evolutionarily highly conserved across species.
Most of the adaptive effects to hypoxia would seem to evoke
cellular protection. Given these facts, the potential detri-
mental effects of hyperoxia need to be considered carefully.
To muddy the waters further, a recent prepublication report of
a retrospective study from the San Diego County Trauma
Registry [6], presented at the American Heart Association
annual meeting, has found an association between both
hypoxaemia and hyperoxaemia with a higher than predicted
mortality in traumatic brain injury. From the 3,515 patients
with traumatic brain injury on the register, 1,012 had docu-
mented hypoxaemia (arterial partial pressure of oxygen
(PaO2) <110 mmHg) and 358 had hyperoxaemia (PaO2
>487 mmHg). In comparison with their Trauma and Injury
Severity Score (TRISS)-predicted mortality, the hypoxaemic
patients had a survival rate 41% lower than predicted and the
hyperoxaemic patients had a survival rate 48% lower than
predicted. The patients with PaO2 in the range 110 to
487 mmHg were found to have a survival rate 77% greater
than predicted.
It is sobering to consider that we still do not fully understand
the pharmacodynamics or pharmacokinetics of oxygen. Until
we do, like so many other interventions the conclusion seems
to be give more than enough but not too much.
From oxygenation to ventilation
Few would contest that minimising the lung injury caused by
intermittent positive pressure ventilation (IPPV) in patients
with acute respiratory distress syndrome (ARDS) is now an
established clinical approach. However, how best to achieve
this remains controversial. A novel and attractively simple
approach has been investigated by Forel and colleagues [7].
They conducted a multicentre, investigator-blinded,
randomised control trial of neuromuscular blockade (NMB)
for 48 hours. They hypothesised that NMB would permit less
injurious IPPV and hence reduce pro-inflammatory cytokine
production by the lungs. ARDS was diagnosed in 51 patients
in the study period, 36 of whom were randomised. Therapy
was started, on average, within 1 day of diagnosis. The 18
patients in the control and intervention groups were
reasonably well matched at baseline, given the small sample
size. It is noteworthy that 28 of the 36 patients had
pneumonia as their primary diagnosis. After 48 hours, pro-
inflammatory cytokine levels in bronchoalveolar lavage fluid
and serum had increased in the control group but not in the
intervention group. This difference was statistically significant.
There was also a statistically significant greater improvement
in PaO2/FiO2 ratio in the NMB group over the 120 hours after
study  entry. As the protocolised ventilatory strategy in this
study was based on the low-tidal-volume ARDSnet study, in
which positive end-expiratory pressure (PEEP) level was
determined by FiO2, this greater improvement in PaO2/FiO2
ratio also resulted in a statistically significant greater reduction
in PEEP and plateau pressures over the 120 hours of
observation. This study was not powered to detect differences
in outcome; indeed, none that were statistically significant were
observed in the duration of mechanical ventilation, number of
ventilator-free days at 28 days or mortality in the intensive care
unit. The authors, together with an accompanying editorial [8],
advocate further investigation of this intervention and make a
coherent argument to support this conclusion.
However, I have several reservations about this intervention.
First, no attempt was made to quantify any positive clinical
consequences of altering the pro-inflammatory cytokine
profile, especially on the incidence of extra-pulmonary organ
dysfunction, nor indeed am I aware of any evidence to
support the hypothesis that stabilising cytokine levels is
associated with better outcomes. Second, to my knowledge
no intervention that has targeted improvement in the PaO2/
FiO2 ratio in ARDS has yet been shown to affect outcome
positively, for example nitric oxide. Third, there is a body of
literature that demonstrates significant physiological benefits
from the maintenance of spontaneous breathing efforts
during IPPV [9]. Fourth, if NMB is to be adopted as a clinical
intervention, there is surely an argument to be made for
starting it at the time of intubation because the maximal
benefit should occur during the initial period of IPPV.
Additionally, if short-term NMB is beneficial as a short-term
adjunct to IPPV then should its use be considered in any
ARDS patient with a rising cytokine profile? Fifth, a duration
of 48 hours was arbitrarily chosen. Given that at least some
of the beneficial effects persisted for at least 72 hours after
cessation, then a shorter period of NMB might be equally
efficacious and, in addition, further reduce the potential for
increasing the incidence of critical illness neuromyopathy. In
conclusion, I am not convinced that this study advances the
current debate on how to best ventilate patients with ARDS.
Cue the rhythm section?
December saw the publication of three papers investigating
the therapeutic potential of intermittent intrapulmonary
percussive ventilation (IPV). This technique, and the devices
that deliver it, have been around for about 20 years. However,
their use has largely been confined to patients with cystic
fibrosis and bronchiectasis [10]. This technique delivers a
high-frequency (up to 10 Hz) of high-flow gas bursts. The
devices can also be used to deliver aerosols; however,
particle size generation and airway deposition are less
effective than conventional nebulisation [11,12]. These
devices provide a diffusive mode of ventilatory support via a
non-invasive, patient-controlled, mouthpiece or mask and via
a variety of mechanisms mobilise respiratory secretions and
facilitate their clearance.Page 3 of 3
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Antonaglia and colleagues have performed a small-scale trial
in 40 patients with an acute exacerbation of chronic
obstructive pulmonary disease (COPD) comparing 40
historical controls, who had received mask ventilation, with
helmet ventilation. In addition, the patients who received
helmet ventilation were randomised to receive either a once-
daily 30-minute standard respiratory physiotherapy session or
a twice-daily 30-minute IPV session, from the second day of
helmet ventilation until the patients achieved at least 24 hours
of support-free ventilation. The IPV group required a median
of 61 hours of ventilatory support, in contrast with 89 and
87 hours in the physiotherapy and historical control groups,
respectively. This equated to a shorter median length of ICU
stay of 7 days, versus 9 and 10 days, respectively. Although
underpowered, this well designed, pragmatic study demon-
strates that as an adjunctive technique IPV offers potential
advantages over current standard therapy. It may be especially
well suited to patients with a significant volume of secretions,
not least as conventional mask/helmet ventilation is usually
performed with dry gas and has the propensity to inhibit
secretion clearance. It is noteworthy that IPV has previously
been shown to be efficacious as a sole intervention in mild to
moderate acute exacerbations of COPD [13].
Clini and colleagues investigated the use of IPV in a small
randomised control trial in a diverse group of slow-to-wean
patients who required the persistence of a tracheostomy,
after liberation from mechanical support, for secretion
management [14]. The control group (n = 21) received two
1-hour chest physiotherapy sessions for 15 days. The inter-
vention group (n = 23) received identical therapy but
preceded by an unspecified period of IPV. Gas exchange,
expiratory muscle strength and pulmonary complications
during the study period and over a 1 month follow-up period
were the study endpoints. Expiratory muscle strength and the
incidence of pneumonia were statistically significantly
increased and decreased, respectively, in the IPV group.
Although hardly ground-breaking, this study demonstrates
that IPV is efficacious when compared with conventional
physiotherapy. This message is perhaps underlined by a
recent systematic review, which finds a paucity of evidence to
support prophylactic chest physiotherapy after abdominal
surgery [15] and other previous negative reviews [16,17].
Tsuruta and colleagues report the safety and efficacy of
superimposing IPV on conventional IPPV, via an endotracheal
tube, in a cohort of 10 obese patients with respiratory failure
secondary to compression atelectasis, who had failed to
improve after optimal IPPV [18]. Although this intervention
somewhat mimics standard high-frequency oscillatory
ventilation in a spontaneously breathing patient, it differs in
that in place of a continuous distending pressure, mandatory
convectional ventilation with conventional tidal volumes was
maintained. Oxygenation improved in all 10 patients. This
coincided with marked radiological improvement. No
outcome data are given.
Overall, a comparatively simple method of respiratory support
seems to have gained a sudden resurgence of interest and
shows early promise as a valuable adjunct to current
therapies.
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